Cargando…
Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study
OBJECTIVE: To estimate the association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder (OAB). DESIGN: A retrospective claims-based study (2007–2015) of patients with OAB; outcomes from a subset were contrasted to a non-OAB comparison. SETTING: Un...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502005/ https://www.ncbi.nlm.nih.gov/pubmed/31061036 http://dx.doi.org/10.1136/bmjopen-2018-026391 |
_version_ | 1783416184080695296 |
---|---|
author | Szabo, Shelagh M Gooch, Katherine Schermer, Carol Walker, David Lozano-Ortega, G Rogula, Basia Deighton, Alison Vonesh, Edward Campbell, Noll |
author_facet | Szabo, Shelagh M Gooch, Katherine Schermer, Carol Walker, David Lozano-Ortega, G Rogula, Basia Deighton, Alison Vonesh, Edward Campbell, Noll |
author_sort | Szabo, Shelagh M |
collection | PubMed |
description | OBJECTIVE: To estimate the association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder (OAB). DESIGN: A retrospective claims-based study (2007–2015) of patients with OAB; outcomes from a subset were contrasted to a non-OAB comparison. SETTING: United States, commercially and Medicare-insured population. PARTICIPANTS: 154 432 adults with OAB and 86 966 adults without OAB, mean age of 56 years, and 67.9% women. MAIN OUTCOME MEASURES: Cumulative anticholinergic burden, a unitless value representing exposure over time, was estimated over the 12 months pre-index (‘at baseline’) and every 6 months post index. Burden was categorised as no burden (0), low burden (1–89), medium burden (90–499) or high burden (500+). Unadjusted rates of falls or fractures were estimated, and the increased risk associated with anticholinergic burden (measured at the closest 6-month interval prior to a fall or fracture) was assessed using a Cox proportional hazards model and a marginal structural model. RESULTS: Median (IQR) baseline anticholinergic burden was 30 (0.0–314.0) and higher among older (≥65 years, 183 [3.0–713.0]) versus younger (<65 years, 13 [0.0–200.0]) adults. The unadjusted rate of falls or fractures over the period was 5.0 per 100 patient-years, ranging from 3.1 (95% CI 3.0–3.2) for those with no burden, to 7.4 (95% CI 7.1–7.6) for those with high burden at baseline. The adjusted risk of falls and fractures was greater with higher anticholinergic burden in the previous 6 months, with an HR of 1.2 (95% CI 1.2 to 1.3) for low burden versus no burden, to 1.4 (95% CI 1.3 to 1.4) for high versus no burden. Estimates from marginal structural models adjusting for time-varying covariates were lower but remained significantly higher with a higher anticholinergic burden. Rates of falls and fractures were approximately 40% higher among those with OAB (vs those without). CONCLUSION: Higher levels of anticholinergic burden are associated with higher rates of falls and fractures, highlighting the importance of considering anticholinergic burden when treating patients with OAB. |
format | Online Article Text |
id | pubmed-6502005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-65020052019-05-21 Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study Szabo, Shelagh M Gooch, Katherine Schermer, Carol Walker, David Lozano-Ortega, G Rogula, Basia Deighton, Alison Vonesh, Edward Campbell, Noll BMJ Open Pharmacology and Therapeutics OBJECTIVE: To estimate the association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder (OAB). DESIGN: A retrospective claims-based study (2007–2015) of patients with OAB; outcomes from a subset were contrasted to a non-OAB comparison. SETTING: United States, commercially and Medicare-insured population. PARTICIPANTS: 154 432 adults with OAB and 86 966 adults without OAB, mean age of 56 years, and 67.9% women. MAIN OUTCOME MEASURES: Cumulative anticholinergic burden, a unitless value representing exposure over time, was estimated over the 12 months pre-index (‘at baseline’) and every 6 months post index. Burden was categorised as no burden (0), low burden (1–89), medium burden (90–499) or high burden (500+). Unadjusted rates of falls or fractures were estimated, and the increased risk associated with anticholinergic burden (measured at the closest 6-month interval prior to a fall or fracture) was assessed using a Cox proportional hazards model and a marginal structural model. RESULTS: Median (IQR) baseline anticholinergic burden was 30 (0.0–314.0) and higher among older (≥65 years, 183 [3.0–713.0]) versus younger (<65 years, 13 [0.0–200.0]) adults. The unadjusted rate of falls or fractures over the period was 5.0 per 100 patient-years, ranging from 3.1 (95% CI 3.0–3.2) for those with no burden, to 7.4 (95% CI 7.1–7.6) for those with high burden at baseline. The adjusted risk of falls and fractures was greater with higher anticholinergic burden in the previous 6 months, with an HR of 1.2 (95% CI 1.2 to 1.3) for low burden versus no burden, to 1.4 (95% CI 1.3 to 1.4) for high versus no burden. Estimates from marginal structural models adjusting for time-varying covariates were lower but remained significantly higher with a higher anticholinergic burden. Rates of falls and fractures were approximately 40% higher among those with OAB (vs those without). CONCLUSION: Higher levels of anticholinergic burden are associated with higher rates of falls and fractures, highlighting the importance of considering anticholinergic burden when treating patients with OAB. BMJ Publishing Group 2019-05-05 /pmc/articles/PMC6502005/ /pubmed/31061036 http://dx.doi.org/10.1136/bmjopen-2018-026391 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Pharmacology and Therapeutics Szabo, Shelagh M Gooch, Katherine Schermer, Carol Walker, David Lozano-Ortega, G Rogula, Basia Deighton, Alison Vonesh, Edward Campbell, Noll Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study |
title | Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study |
title_full | Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study |
title_fullStr | Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study |
title_full_unstemmed | Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study |
title_short | Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study |
title_sort | association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: us-based retrospective cohort study |
topic | Pharmacology and Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502005/ https://www.ncbi.nlm.nih.gov/pubmed/31061036 http://dx.doi.org/10.1136/bmjopen-2018-026391 |
work_keys_str_mv | AT szaboshelaghm associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy AT goochkatherine associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy AT schermercarol associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy AT walkerdavid associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy AT lozanoortegag associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy AT rogulabasia associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy AT deightonalison associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy AT voneshedward associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy AT campbellnoll associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy |